NO20034433L - Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil - Google Patents
Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracilInfo
- Publication number
- NO20034433L NO20034433L NO20034433A NO20034433A NO20034433L NO 20034433 L NO20034433 L NO 20034433L NO 20034433 A NO20034433 A NO 20034433A NO 20034433 A NO20034433 A NO 20034433A NO 20034433 L NO20034433 L NO 20034433L
- Authority
- NO
- Norway
- Prior art keywords
- rapamycin
- fluorouracil
- atineoplastic
- gemcitabine
- compositions
- Prior art date
Links
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002949 fluorouracil Drugs 0.000 title abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
- 229960002930 sirolimus Drugs 0.000 title abstract 2
- 229960005277 gemcitabine Drugs 0.000 title 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28238801P | 2001-04-06 | 2001-04-06 | |
| US28238501P | 2001-04-06 | 2001-04-06 | |
| PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034433D0 NO20034433D0 (no) | 2003-10-03 |
| NO20034433L true NO20034433L (no) | 2003-11-25 |
Family
ID=26961412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034433A NO20034433L (no) | 2001-04-06 | 2003-10-03 | Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1385551B1 (de) |
| JP (1) | JP2004525950A (de) |
| KR (1) | KR100862178B1 (de) |
| CN (1) | CN1309421C (de) |
| AT (1) | ATE406892T1 (de) |
| AU (1) | AU2007242958A1 (de) |
| BR (1) | BR0208627A (de) |
| CA (1) | CA2442849A1 (de) |
| DE (1) | DE60228699D1 (de) |
| EA (1) | EA010184B1 (de) |
| ES (1) | ES2312568T3 (de) |
| HU (1) | HUP0304093A3 (de) |
| IL (1) | IL157898A0 (de) |
| MX (1) | MXPA03009092A (de) |
| NO (1) | NO20034433L (de) |
| NZ (1) | NZ540047A (de) |
| PL (1) | PL363991A1 (de) |
| PT (1) | PT1385551E (de) |
| SG (1) | SG152906A1 (de) |
| SI (1) | SI1385551T1 (de) |
| WO (1) | WO2002080975A1 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| EP3342411B1 (de) | 2001-02-19 | 2019-08-21 | Novartis Pharma AG | Rapamycin-derivat zur behandlung von bauchspeicheldrüsenkrebs |
| GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| EP1732583A4 (de) * | 2004-02-26 | 2009-08-12 | Penn State Res Found | Kombinationstherapien zur behandlung von neoplasie unter verwendung des opioid-wachstumsfaktor-rezeptors |
| WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| ZA200706804B (en) | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| EP1925676A4 (de) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Testverfahren für die wirkung eines vaskularisierungsinhibitors |
| KR101354828B1 (ko) * | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합 |
| AU2006315512B2 (en) * | 2005-11-14 | 2012-11-01 | Ariad Pharmaceuticals, Inc. | Administration of an mTOR inhibitor to treat patients with cancer |
| GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| NO20220050A1 (no) * | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| EP1880723A1 (de) * | 2006-07-14 | 2008-01-23 | Novartis AG | Kombination aus mTOR Inhibitor und Antifolat Verbindung |
| CA2637069A1 (en) * | 2006-01-12 | 2007-07-19 | Novartis Ag | Combination of mtor inhibitor and antipolate compound |
| WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| WO2007124252A2 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| EP2054061A4 (de) * | 2006-08-02 | 2009-09-02 | Ariad Pharma Inc | Kombinationstherapie |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| WO2008044068A2 (en) * | 2006-10-11 | 2008-04-17 | Fusion Antibodies Limited | Combination therapy |
| AU2007319825B2 (en) | 2006-11-14 | 2014-01-23 | Ariad Pharmaceuticals, Inc. | Oral formulations |
| CN101616671A (zh) | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| KR20150002886A (ko) * | 2007-03-07 | 2015-01-07 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CA2725598C (en) | 2008-06-17 | 2013-10-08 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
| MX2011001318A (es) | 2008-08-04 | 2011-03-04 | Wyeth Llc | Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina. |
| EP2416774B1 (de) | 2009-04-06 | 2015-11-04 | Wyeth LLC | Behandlungsschema mit neratinib gegen brustkrebs |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (de) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen |
| RU2015115397A (ru) | 2012-12-21 | 2017-01-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аморфная форма производного хинолина и способ его получения |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| AU2017241524B2 (en) | 2016-03-28 | 2021-07-08 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| TWI821200B (zh) | 2017-09-27 | 2023-11-11 | 美商英塞特公司 | Tam抑制劑之鹽 |
| US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
| EP4114401A1 (de) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Kombinationstherapie mit axl/mer- und pd-1/pd-l1-inhibitoren |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| NZ336676A (en) * | 1997-01-24 | 2000-01-28 | Norsk Hydro As | Gemcitabine esters or amides useful as anti-cancer and anti-viral agents |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en not_active Ceased
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 EP EP02726710A patent/EP1385551B1/de not_active Expired - Lifetime
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active Expired - Fee Related
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EA010184B1 (ru) | 2008-06-30 |
| HK1060062A1 (en) | 2004-07-30 |
| CN1545419A (zh) | 2004-11-10 |
| CN1309421C (zh) | 2007-04-11 |
| HUP0304093A3 (en) | 2008-08-28 |
| EP1385551B1 (de) | 2008-09-03 |
| EP1385551A1 (de) | 2004-02-04 |
| BR0208627A (pt) | 2004-03-09 |
| MXPA03009092A (es) | 2004-02-12 |
| KR20040007491A (ko) | 2004-01-24 |
| SI1385551T1 (sl) | 2008-12-31 |
| KR100862178B1 (ko) | 2008-10-09 |
| HUP0304093A2 (hu) | 2004-04-28 |
| IL157898A0 (en) | 2004-03-28 |
| DE60228699D1 (de) | 2008-10-16 |
| WO2002080975A1 (en) | 2002-10-17 |
| PT1385551E (pt) | 2008-11-03 |
| ES2312568T3 (es) | 2009-03-01 |
| EA200301091A1 (ru) | 2004-02-26 |
| NO20034433D0 (no) | 2003-10-03 |
| JP2004525950A (ja) | 2004-08-26 |
| CA2442849A1 (en) | 2002-10-17 |
| AU2007242958A1 (en) | 2008-01-10 |
| ATE406892T1 (de) | 2008-09-15 |
| NZ540047A (en) | 2007-01-26 |
| SG152906A1 (en) | 2009-06-29 |
| PL363991A1 (en) | 2004-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034433D0 (no) | Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil | |
| ECSP045245A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados | |
| NO20034094D0 (no) | Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat | |
| ECSP056001A (es) | Combinaciones antineoplásicas | |
| BR0211769A (pt) | Combinações antineoplásicas | |
| NO20032181D0 (no) | Anvendelse av CCI-779 som et antineoplastisk middel | |
| AR028512A1 (es) | Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas | |
| DK1401806T3 (da) | Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler | |
| NO20041998L (no) | Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem | |
| NO20042288L (no) | Kinazolinderivater som antitumormidler | |
| CY1111613T1 (el) | Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv | |
| BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
| NO20043313L (no) | Anvendelse av COX-2 inhibitorer i kombinasjon med antivirale midler for behandling av Papilloma virus infeksjoner | |
| NO20052534D0 (no) | Oksazolidinon- og/eller isokazolinderivater som antibakterielle stoffer | |
| NO20071871L (no) | Fosfoindoler som HIV-inhibitorer. | |
| NO20040175L (no) | Acylsemikarbazider som cyklinavhengige kineaseinhibitorer anvendelige som anti-kreft- og anti-proliferative midler | |
| BR0210101A (pt) | Combinações antineoplásticas | |
| ECSP034790A (es) | Combinaciones antineoplásticas tales como rapamicin junto con gemcitabina o fluorouracil | |
| ITVR20010031A0 (it) | Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative. | |
| BR0309923B1 (pt) | Formulação aquosa de poliuretano, e, uso da mesma | |
| NO20061402L (no) | Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler | |
| DK1545553T3 (da) | Anvendelse af alkylphosphocholiner i kombination med antitumormedikamenter | |
| FI20040531A7 (fi) | Insuliiniresistenttien tilojen hoitaminen ja diagnosointi | |
| IT1317920B1 (it) | S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer. | |
| DE60304360D1 (de) | N-aryl-2-oxazolidinone und deren derivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |